Mirum files Form 144 to sell 7,287 shares

Mirum Pharmaceuticals submitted a Form 144 notice to sell 7,287 shares of Common Stock, tied to Restricted Stock Units vesting under a registered plan.

Rhea-AI Filing Summary

Mirum Pharmaceuticals submitted a Form 144 notice to sell 7,287 shares of Common Stock, tied to Restricted Stock Units vesting under a registered plan. The filing lists the proposed disposition by an issuer-related broker on 03/15/2026.

The filing also discloses two recent sales by Eric Bjerkholt: 1,421 shares sold on 01/22/2026 for $132,615.15 and 1,053 shares sold on 01/26/2026 for $101,290.18. The notice records the broker as Morgan Stanley Smith Barney LLC.

Insights

Corporate Governance Analyst

Routine Form 144 notice for vested RSUs; prior small open-market dispositions visible.

This Form 144 records a proposed sale of 7,287 shares arising from RSUs vesting under a registered plan. The filing names Morgan Stanley Smith Barney LLC as the broker and dates the securities to 03/15/2026.

Two earlier sales by an insider, totaling 2,474 shares across January dates, are listed with proceeds. The filing appears administrative and does not on its face indicate material company-level change; further filings would show whether sales occur.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Mirum's Form 144 for MIRM mean?

A Form 144 notifies the SEC of a proposed sale by an insider or related party. This filing reports a proposal to sell 7,287 shares tied to vested RSUs under a registered plan, with brokerage involvement dated 03/15/2026.

Who is listed as selling or handling the sale in the MIRM filing?

The filing names Morgan Stanley Smith Barney LLC as the broker handling the transaction. The securities are identified as Common Stock and linked to RSUs vesting under a registered plan on 03/15/2026.

Were there recent insider sales disclosed for MIRM before this Form 144?

Yes. The filing discloses two prior sales by Eric Bjerkholt: 1,421 shares on 01/22/2026 for $132,615.15 and 1,053 shares on 01/26/2026 for $101,290.18, as reported in the document.

Do these Form 144 entries mean Mirum will receive proceeds?

The filing describes a sale of shares tied to vested RSUs and lists a broker, but it does not specify proceeds treatment to the issuer. The Form 144 itself is a notice of proposed sale, not a confirmation of proceeds allocation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 07:03 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001197350
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MIRUM PHARMACEUTICALS, INC.
SEC File Number	001-38981
Address of Issuer	989 E HILLSDALE BLVD., SUITE 300 FOSTER CITY CALIFORNIA 94404
Phone	650-667-4085
Name of Person for Whose Account the Securities are To Be Sold	ERIC BJERKHOLT
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 8th Floor New York NY 10004	7287	675067.68	60341617	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/15/2026	Restricted Stock Units vesting under registered plan	Issuer			7287	03/15/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Bjerkholt c/o Mirum Pharmaceuticals, Inc. 989 E Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/22/2026	1421	132615.15
Eric Bjerkholt c/o Mirum Pharmaceuticals, Inc. 989 East Hillsdale Boulevard, Suite 300 Foster City CA 94404	Common Stock	01/26/2026	1053	101290.18

144: Remarks and Signature

Remarks	This is a sell-to-cover transaction for taxes owed related to recent vesting of stock unit awards granted by the Issuer.
Date of Notice	03/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/23/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Judit Ryvkin, Attorney-in-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)